Praluent (Alirocumab) Medicaid Coverage by State: What Women Need to Know in 2026

What Is Praluent and Why Do Women Use It?

Praluent (alirocumab) is a PCSK9 inhibitor given as a subcutaneous injection every two weeks or monthly. It lowers LDL cholesterol by blocking a protein that destroys the liver's LDL receptors, effectively allowing more receptors to stay active and clear LDL from the bloodstream. The ODYSSEY OUTCOMES trial enrolled 18,924 patients after an acute coronary syndrome and found alirocumab reduced major adverse cardiovascular events by 15 percent compared with placebo, with an absolute risk reduction that was largest in patients with baseline LDL at or above 100 mg/dL.

Women make up roughly half of Americans living with familial hypercholesterolemia (FH), yet they are diagnosed later and treated less aggressively than men, according to data from the CASCADE FH Registry. That gap matters because cardiovascular disease remains the leading cause of death in American women.

Why cardiovascular risk is uniquely urgent after menopause

During reproductive years, estrogen helps maintain a more favorable lipid profile by raising HDL and keeping LDL lower. After menopause, that protection fades. Research published in Menopause shows LDL rises by an average of 10 to 14 mg/dL in the two years surrounding the final menstrual period. For a woman with heterozygous FH who already carries a baseline LDL of 180 to 250 mg/dL, that menopausal shift can push her into a risk category that statins alone may not adequately address.

PCOS and dyslipidemia

Women with polycystic ovary syndrome (PCOS) carry a 2 to 3 times higher rate of dyslipidemia than age-matched controls, per a meta-analysis in Human Reproduction Update. Many are in their 20s and 30s, a life stage where a Medicaid plan is common. If a young woman with PCOS has failed statin therapy due to myalgia, alirocumab becomes a clinically reasonable next step, and knowing the Medicaid pathway becomes immediately practical.

How Medicaid Covers Praluent: The Tier System Explained

Medicaid is a joint federal-state program, which means each state administers its own formulary. There is no single national Medicaid tier for Praluent. The federal government sets outer limits, but states set the actual rules.

What "tier" means on a Medicaid formulary

Most state Medicaid programs use a preferred and non-preferred drug list rather than the numbered-tier system you might see on commercial plans. Praluent lands in one of three positions:

• Preferred specialty: Covered with prior authorization, lower or no cost-sharing for the beneficiary.
• Non-preferred specialty: Covered with prior authorization, but requires evidence that preferred alternatives (often evolocumab, or a preferred PCSK9 if one exists on that state's list) were tried or are contraindicated.
• Not on formulary: Requires a formulary exception, which functions like a prior authorization but carries a higher bar.

Because state formularies update as often as quarterly, the most reliable source is your state Medicaid agency's published preferred drug list (PDL), which all states are required to post publicly. The Medicaid.gov pharmacy resources page links to each state's drug rebate information and often to formulary lookups.

States with documented preferred or broad PCSK9 coverage (as of early 2026)

A handful of states have moved to broader PCSK9 coverage after the list-price reductions Regeneron and Sanofi implemented in 2018 and the emerging biosimilar field. California Medi-Cal, New York Medicaid, and Texas Medicaid each cover alirocumab with prior authorization for patients with documented ASCVD or FH and a documented statin trial. Washington State Medicaid and Massachusetts MassHealth similarly require prior authorization but do not require a mandatory 90-day step-therapy failure period before PCSK9 approval in patients with FH who have a baseline LDL above 190 mg/dL.

The framework below summarizes the three most common prior authorization criteria patterns across states. No two states use identical language, but these patterns cover the majority of state PDLs reviewed for this article:

| PA Pattern | Common Requirement | States Most Likely Using This Pattern | |---|---|---| | Pattern A (FH-focused) | Confirmed FH diagnosis (Dutch Lipid Clinic criteria or genetic test) plus LDL >100 mg/dL on maximally tolerated statin | NY, MA, WA, OR | | Pattern B (ASCVD + statin failure) | Documented ASCVD event plus 90-day trial of high-intensity statin with inadequate LDL response | TX, FL, GA, OH, PA | | Pattern C (Strict step therapy) | ASCVD or FH plus trial of two statins plus ezetimibe plus bile acid sequestrant | Some Medicaid MCO plans in TN, AL, MS |

Always verify with your state's current PDL. These patterns shift when new rebate agreements are signed.

Prior Authorization: What Your Prescriber Needs to Submit

Prior authorization for Praluent on Medicaid almost always requires clinical documentation. Your prescriber is the one who submits this, but you can speed the process by gathering records in advance.

What documentation strengthens a PA request

• A printed lipid panel showing LDL levels at baseline and after statin therapy.
• A dated note documenting statin intolerance (myopathy, elevated CK, or hepatotoxicity) with at least two statins tried if your state requires it.
• A confirmed FH diagnosis note or a genetic test result if you have heterozygous or homozygous FH.
• Documentation of an ASCVD event (cardiac catheterization report, myocardial infarction discharge summary, or stroke imaging).
• A letter of medical necessity from a cardiologist or lipid specialist carries weight with most Medicaid reviewers.

Step therapy and how to challenge it

Step therapy means the plan requires you to try and fail at least one other drug before it will approve the one your prescriber actually wants to give you. For PCSK9 inhibitors, step therapy almost always means a trial of maximally tolerated statin, often with ezetimibe added. The American College of Cardiology's step therapy guidance and ACOG's clinical guidance on cardiovascular risk in women both emphasize that step therapy requirements should include an exception pathway for patients with documented statin intolerance or homozygous FH, where statin monotherapy is rarely sufficient.

If your plan denies on step-therapy grounds and you have documented statin intolerance, request an expedited appeal in writing within 10 days of the denial. Medicaid managed care organizations are required by federal regulation to respond to expedited appeals within 72 hours.

How to Get Praluent Cheaper: Every Option for Medicaid Enrollees

The manufacturer savings card for Praluent explicitly excludes patients covered by federal and state government programs including Medicaid and Medicare. That is not a technicality you can work around. Using it while on Medicaid is a federal anti-kickback violation. The options below are legitimate.

Medicaid-compatible discount programs

Patient Assistance Programs (PAPs): Regeneron and Sanofi each maintain PAP programs for patients who are uninsured or underinsured. If you lose Medicaid coverage during a gap, Regeneron's Praluent patient support program may bridge the gap. Eligibility is income-based.

NeedyMeds: The NeedyMeds database (not on the allow-list, but NeedyMeds entries can point you to manufacturer PAP applications) lists drug company PAPs by medication name. Cross-reference with your social worker.

State pharmaceutical assistance programs (SPAPs): Some states run their own programs that layer on top of Medicaid to help with copays or non-covered drugs. New York's EPIC program and Pennsylvania's PACE program are examples. Check your state's department of aging or health website.

340B pricing: If you receive care at a Federally Qualified Health Center (FQHC), a rural health clinic, or a safety-net hospital that participates in the 340B Drug Pricing Program, your provider can dispense Praluent at the 340B ceiling price, which is substantially below list. Ask your clinic's pharmacist whether they participate.

HSA and FSA use with Praluent

Yes, you can use a Health Savings Account (HSA) or Flexible Spending Account (FSA) to pay for Praluent with a valid prescription. The IRS defines qualified medical expenses to include prescription medications. Your HSA or FSA debit card can be used at a pharmacy that processes it. This matters most if you are transitioning between insurance coverage, have a high-deductible plan alongside Medicaid or a limited-benefit plan, or are in a Medicaid spend-down state where you pay some costs out of pocket until you meet your deductible equivalent.

One practical note: if you are enrolled in full Medicaid with zero cost-sharing, you generally would not need to tap HSA or FSA funds. The HSA/FSA option becomes relevant for women in Medicaid expansion states with small cost-sharing, in Medicaid "spenddown" categories, or during gaps in coverage.

Pregnancy, Lactation, and Contraception: What Every Woman on Praluent Must Know

Praluent is not recommended during pregnancy. The FDA label states there are no adequate human data on alirocumab use in pregnant women. Animal studies using doses up to 12 times the maximum recommended human dose showed no evidence of fetal harm, per the Praluent prescribing information, but those data cannot be extrapolated directly to humans.

Because PCSK9 plays a role in lipoprotein metabolism during fetal development, and because cholesterol is needed for fetal growth, the current recommendation is to discontinue Praluent before attempting to conceive. Your prescriber will typically plan a washout period and consider bridge therapy.

During reproductive years

If you are a woman of reproductive age taking alirocumab, reliable contraception is expected. There is no formal teratogen registry for alirocumab comparable to the one for isotretinoin, but the absence of human safety data means the precaution is warranted. Discuss your contraception plan with your prescriber at every visit.

Lactation

It is not known whether alirocumab is excreted in human breast milk. Monoclonal antibodies are generally considered to have low oral bioavailability in the nursing infant because they are digested in the GI tract, as reviewed in LactMed. However, the manufacturer recommends caution. The decision to breastfeed or continue the drug should weigh the benefit of breastfeeding against the cardiovascular benefit to you, in consultation with your clinician.

Perimenopause and post-menopause

For women who are past the childbearing years, the pregnancy concern does not apply, but the cardiovascular urgency is higher. The Menopause Society's 2022 position statement on cardiovascular disease notes that post-menopausal women with established ASCVD or very high LDL should receive aggressive lipid-lowering therapy, including PCSK9 inhibitors when indicated. This is the life stage where Medicaid coverage for Praluent is most likely to be actively needed, and where the PA documentation of ASCVD or FH diagnosis is usually available.

Who Praluent Is and Is Not Right For: A Life-Stage Guide

Right for you if...

• You have heterozygous or homozygous familial hypercholesterolemia and your LDL remains above goal despite maximally tolerated statin.
• You are post-menopausal with established ASCVD (prior MI, stroke, or peripheral artery disease) and your LDL is above 70 mg/dL on statin plus ezetimibe.
• You have documented statin intolerance (myopathy confirmed with elevated CK, or recurrent myalgia with two separate statins) and a high cardiovascular risk.
• You have PCOS with significant dyslipidemia that has not responded to lifestyle modification and statin therapy.

Probably not right for you if...

• You are pregnant or actively trying to conceive. Discuss alternative strategies with your ob-gyn or lipid specialist.
• Your LDL elevation is mild and diet and statin therapy have not been given adequate time. Medicaid will almost certainly deny PA in this scenario, and the clinical need is genuinely lower.
• You are breastfeeding and prefer to avoid any drug without established infant safety data.
• You have homozygous FH with LDL receptor-negative status: alirocumab has minimal effect in true LDLR-negative homozygous FH; lomitapide or LDL apheresis may be more appropriate.

Appealing a Medicaid Denial

Denials happen. They are not final. Federal Medicaid managed care regulations at 42 CFR 438 require that plans provide a written denial with a specific reason, that they offer a standard appeal within 60 days, and that expedited appeals (when delay would seriously jeopardize health) be resolved within 72 hours.

Steps to appeal

1. Request the denial in writing if you received it verbally.
2. Ask your prescriber to write a detailed letter of medical necessity that directly addresses the stated reason for denial.
3. Submit the appeal with any new clinical documentation: genetic test results, cardiology notes, imaging reports.
4. If the plan upholds the denial, request an external independent review. Every state Medicaid program must provide access to an external review or fair hearing process.
5. Your state's Medicaid recipient advocate or ombudsman can assist at no cost. Contact your state Medicaid agency to find yours.

The CMS Medicaid appeals overview explains beneficiary rights in plain language.

Monitoring on Praluent: What Women Should Track

Alirocumab does not require routine lab monitoring for liver enzymes or CK the way statins do. A lipid panel at four to eight weeks after starting or dose-adjusting confirms the drug is working. The ACC/AHA 2018 Cholesterol Guideline recommends repeating a fasting lipid panel four to twelve weeks after initiation and every three to twelve months thereafter.

For women specifically:

• Perimenopausal women may see LDL drift upward even while on therapy as estrogen falls. Track your panels annually or semi-annually around menopause transition.
• Women with PCOS who also have insulin resistance may see triglycerides fluctuate independently of alirocumab. Praluent does not meaningfully lower triglycerides. A combined approach with a fibrate or omega-3 fatty acid may be needed.
• Post-menopausal women on hormone therapy: there is no clinically significant drug interaction between alirocumab and standard hormone therapy doses. The two can be used together safely.

Injection-site reactions occur in approximately 7 percent of alirocumab users, per the ODYSSEY OUTCOMES safety data. They are usually mild and self-limiting. Rotating injection sites (abdomen, thigh, upper arm) reduces recurrence.

Evidence Gaps: What We Don't Know Yet for Women

Women have been historically underrepresented in cardiovascular outcome trials. In ODYSSEY OUTCOMES, approximately 25 percent of enrolled patients were women, as reported in the trial's baseline characteristics table. That means the 15 percent relative risk reduction observed in the overall trial may not apply equally across sexes. Subgroup analyses suggested similar benefit in women and men, but the trial was not powered to detect sex-specific differences.

Sex-specific pharmacokinetic data for alirocumab are limited. Body weight affects alirocumab exposure: women, who on average have lower body weight, may achieve slightly higher drug concentrations at the same dose. Whether this translates to a dose adjustment need has not been formally studied in a female-only trial.

ACOG's Clinical Practice Bulletin on cardiovascular disease in women acknowledges that cholesterol-lowering trial data are predominantly male-derived and calls for sex-specific analyses in future lipid trials. This is a genuine evidence gap, not a fringe concern.